Evidence map›Paper›PMID 37490033›Full record

ArticleDalton transactions (Cambridge, England : 2003)2023

Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.

Amarasooriya M D S Jayawardhana, Srijana Bhandari, Ariela W Kaspi-Kaneti, Man Kshetri, Zihan Qiu, May Cheline, Hao Shen, Barry D Dunietz, Yao-Rong Zheng

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Amarasooriya M D S JayawardhanaDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.
Srijana BhandariDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.
Ariela W Kaspi-KanetiDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.
Man KshetriDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.
Zihan QiuDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.
May ChelineDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.ORCID http://orcid.org/0000-0001-6768-9197
Hao ShenDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.ORCID http://orcid.org/0000-0002-4821-7984
Barry D DunietzDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.ORCID http://orcid.org/0000-0002-6982-8995
Yao-Rong ZhengDepartment of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA. yzheng7@kent.edu.ORCID http://orcid.org/0000-0003-4605-1121
Kent State University · US

Funding

Development of Novel Metal-Based Supramolecular Therapeutics for Ovarian CancerR15CA249712 · NCI · KENT STATE UNIVERSITY · PI ZHENG, YAORONG · 2021 to 2021
$455k
NCI NIH HHS R15 CA249712
6 · The paper itself

Abstract

We hereby engineered photoactivatable Pt(IV) metallodrugs that harness CD36 to target ovarian cancer cells. Pt(IV) compounds mimic the structure of fatty acids and take advantage of CD36 as a "Trojan horse" to gain entry into the cells. We confirmed that CD36-dependent entry occurs using graphite furnace atomic absorption spectroscopy with ovarian cancer cells expressing different levels of CD36 and a CD36 inhibitor, SSO. Once the Pt(IV) metallodrugs enter the cancer cells, they can be activated to form Pt(II) with characteristics of cisplatin under visible light (490 nm) irradiation, promoting photoinduced electron transfer from the attached fluorophore to the metal center. This light-induced activation can increase the cytotoxicity of the Pt(IV) metallodrugs by up to 20 times toward ovarian cancer cells, inducing DNA damage and enabling efficient elimination of drug-resistant cancer cells.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsProdrugsCell Line, TumorCisplatinFemaleHumansLightOrganoplatinum CompoundsPlatinumAntineoplastic AgentsCisplatinOrganoplatinum CompoundsPlatinumProdrugs

Identifiers

PMID37490033
PMCPMC11298056
OpenAlexW4384079956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.